Oxford, UK – 29 November 2011. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has launched its brand new website. The new content-rich site provides authoritative insight into the latest developments, tools and issues in genomics research. Intuitive navigation makes it easy for users to find relevant resources matching their requirements, including insightful whitepapers and application notes, discussion topics via the new forum section, as well as detailed information on OGT’s products and services.
The new site utilises a totally new webpage design that maximises usability. Particular emphasis has been given to encouraging customer interaction and feedback though the use of discussion boards, opinion polls, social media sharing and the facility to post comments on all articles and news items. All content is connected and indexed ensuring that users always find what they are looking for, while suggesting relevant additional pages to aid user discovery. The unique navigation structure allows users to rapidly select the most relevant research area for their needs from clinical genetics, genomic services and diagnostic biomarkers.
To see what the new site has to offer you, visit www.ogt.co.uk. Also, you could win an Amazon Kindle just by completing our short website survey.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: products@ogt.co.uk
W: www.ogt.co.uk
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT delivers tailored biomarker discovery solutions that optimise drug and diagnostic development programmes. With expertise in genomic and proteomic diagnostic biomarkers, OGT provides highly specific customised biomarker panels for cancer and other diseases, both for direct sale and also for collaboration with partner companies.
CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
